Skip to main content

Effective and Affordable Flu Vaccines for the World

Project description

Next-generation flu vaccines

Influenza affects millions of people, with 500 000 casualties annually. Current vaccine effectivity is around 40 %, meaning that 60 % of those vaccinated are not sufficiently protected. The EU-funded INDIGO project involves public and private R&D organisations in the EU, India and United States for the development of two influenza vaccine concepts with the goal to achieve < 10 % instead of 60 % non-responders, lower costs and better accessibility. The first concept combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel adjuvant, aiming to obtain proof-of-concept in phase I and IIa trials within 5 years. The second concept is based on innovations including a recombinant viral hemagglutinin with increased immunogenicity, a potent adjuvant and needle-free delivery by intradermal patches. The plans are realistic with a high probability to deliver next-generation flu vaccines.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/influenza

Call for proposal

H2020-SC1-2019-Single-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 459 697,63

Participants (14)

LITEVAX BV
Netherlands
EU contribution
€ 1 058 653,62
Address
Akkersestraat 50
4061BJ Ophemert
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITEIT GENT
Belgium
EU contribution
€ 2 422 283,75
Address
Sint Pietersnieuwstraat 25
9000 Gent
Activity type
Higher or Secondary Education Establishments
EXPRES2ION BIOTECHNOLOGIES APS
Denmark
EU contribution
€ 610 337,50
Address
Agern Alle 1
2970 Horsholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STANIPHARM
France
EU contribution
€ 740 250
Address
Rue Jaques Monod 5
542500 Champigneulles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CELLVAX
France
EU contribution
€ 990 442,50
Address
19 Avenue Du Professeur Cadiot
94700 Maisons-alfort
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
VIROCLINICS BIOSCIENCES BV
Netherlands
EU contribution
€ 944 990
Address
Marconistraat 16
3029 AK Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 943 281,25
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE
India
EU contribution
€ 0
Address
Ncr Biotech Science Cluster 3Rd Milestone Haryana
121001 Faridabad
Activity type
Research Organisations
CBCI Society for Medical Education
India
EU contribution
€ 0
Address
St. John's National Academy Of Health Sciences
560034 Bangalore
Activity type
Higher or Secondary Education Establishments
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
India
EU contribution
€ 0
Address
Anusandhan Bhawan, Rafi Marg 2
110001 New Dehli
Activity type
Research Organisations
CHRISTIAN MEDICAL COLLEGE VELLORE
India
EU contribution
€ 0
Address
Thorapadi Bagayam
632002 Vellore
Activity type
Higher or Secondary Education Establishments
GENNOVA BIOPHARMACEUTICALS LIMITED
India
EU contribution
€ 0
Address
Emcure House T 184 Midc Bhosari
411026 Pune
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CLINICAL DEVELOPMENT SERVICES AGENCY
India
EU contribution
€ 0
Address
Thsti Building Ncr Biotech Science Cluster 3Rd Milestone Gurugram Faridabad Expessway
121001 Faridabad
Activity type
Research Organisations
EPIVAX INC
United States
EU contribution
€ 806 042,75
Address
188 Valley St Suite 424
02909 2468 Providence
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)